Bristol-Myers Squibb announces charitable donation of $1 million

Bristol-Myers SquibbBristol-Myers Squibb Company today announced donations totaling $1 million in 2013 to four nonprofit organizations that support patients with cancer. The donations will fund the development and availability of educational materials for patients and caregivers about the emerging field of cancer research and treatment called immuno-oncology. Bonnie Addario Lung Cancer Foundation, Cancer Support Community, LUNGevity, and Society for Immunotherapy of Cancer each received a $250,000 charitable contribution to advance their independent educational initiatives.

"Bristol-Myers Squibb is committed to leading advances in immuno-oncology, from early discovery and clinical development to providing education and access to care for patients," said Joseph Leveque, MD, vice president, Oncology, U.S. Medical, Bristol-Myers Squibb. "We are proud to support these organizations in their efforts to help educate patients and caregivers about this rapidly evolving area of cancer research and treatment."

Surgery, radiation, cytotoxic or targeted therapies have represented the mainstay of cancer treatment over the last several decades, but long-term survival and a positive quality of life have remained elusive for many patients with advanced disease. To address this unmet medical need, Bristol-Myers Squibb is leading advances in immuno-oncology.

Immuno-oncology is based on the premise that the immune system is the body's most powerful and effective tool for recognizing and fighting disease. Unlike traditional therapies that target the tumor, immuno-oncology agents are designed to harness the natural capabilities of the patient's immune system to fight cancer by targeting the very same pathways that tumor cells use to evade recognition and distribution. The goal of immuno-oncology is to change survival expectations and the way that patients live with cancer.

About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

Most Popular Now

Cannabis extract helps reset brain function in psy…

Research from King's College London has found that a single dose of the cannabis extract cannabidiol can help reduce brain function abnormalities seen in people with psyc...

For first time in 40 years, cure for acute leukemi…

Acute myeloid leukemia is one of the most aggressive cancers. While other cancers have benefitted from new treatments, there has been no encouraging news for most leukemi...

Consuming milk at breakfast lowers blood glucose t…

A change in breakfast routine may provide benefits for the management of type 2 diabetes, according to a new study published in the Journal of Dairy Science. H. Douglas G...

New cancer treatment uses enzymes to boost immune …

Researchers at The University of Texas at Austin have developed a new approach to treating cancer using enzyme therapy. The enzyme, PEG-KYNase, does not directly kill can...

Bayer accelerates six new startups

Changing the experience of health: that's the focus of the six startups which the Bayer G4A team has included in the Accelerator program this year. The young companies fr...

Novartis receives European Commission approval of …

Novartis today announced that the European Commission (EC) has approved Kymriah® (tisagenlecleucel, formerly CTL019). The approved indications are for the treatment of pe...

Shire completes sale of oncology franchise

Shire plc (LSE: SHP, NASDAQ: SHPG) announces today that it has completed the sale of its Oncology franchise to Servier S.A.S. for $2.4 billion. The franchise includes the...

Antioxidant reduces risk for second heart attack, …

Doctors have long known that in the months after a heart attack or stroke, patients are more likely to have another attack or stroke. Now, a paper in the Journal of the A...

SOLAR-1 trial of Novartis investigational alpha-sp…

Novartis today announced the global Phase III SOLAR-1 trial evaluating the investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) has met the primary endpoint s...

Novartis to divest the Sandoz US dermatology busin…

Novartis today announced it has agreed to sell selected portions of its Sandoz US portfolio, specifically the Sandoz US dermatology business and generic US oral solids po...

New tablet production facility in Ingelheim: Cente…

Boehringer Ingelheim held a groundbreaking ceremony for the construction of a new production facility for innovative drugs. This new Solids Launch facility will focus on ...

Tezepelumab granted Breakthrough Therapy Designati…

AstraZeneca and its partner Amgen Inc. (Amgen) today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for tezepelumab...